LEDA Pharma: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
LEDA Pharma
Largest movements
- Tangible fixed assets -€8,648
down €8,648 (-9.9%), from €87,389 to €78,741
of which Land and buildings: -€8,100
- Receivables within one year +€1,548
up €1,548 (+13.9%), from €11,152 to €12,700
- Debts after one year -€14,175
down €14,175 (-21.7%), from €65,286 to €51,110
- Profit (loss) carried forward +€6,990
up €6,990 (+10.9%), from -€64,211 to -€57,221
- Financial charges -€1,301
down €1,301 (-24.3%), from €5,362 to €4,061
- Gross operating margin +€792
up €792 (+3.8%), from €21,054 to €21,846
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €99,221 | €91,792 | -€7,430 | -7.5% |
| Fixed assets | 21/28 | €87,389 | €78,741 | -€8,648 | -9.9% |
| Tangible fixed assets | 22/27 | €87,389 | €78,741 | -€8,648 | -9.9% |
| Land and buildings | 22 | €86,177 | €78,077 | -€8,100 | -9.4% |
| Plant, machinery and equipment | 23 | €1,212 | €664 | -€548 | -45.2% |
| Current assets | 29/58 | €11,832 | €13,051 | +€1,218 | +10.3% |
| Amounts receivable within one year | 40/41 | €11,152 | €12,700 | +€1,548 | +13.9% |
| Other amounts receivable | 41 | €11,152 | €12,700 | +€1,548 | +13.9% |
| Current investments | 50/53 | - | €351 | +€351 | |
| Cash at bank and in hand | 54/58 | €306 | - | -€306 | |
| Deferred charges and accrued income | 490/1 | €374 | - | -€374 | |
| Total equity and liabilities | 10/49 | €99,221 | €91,792 | -€7,430 | -7.5% |
| Equity | 10/15 | -€58,011 | -€51,021 | +€6,990 | +12.0% |
| Contributions | 10/11 | €6,200 | €6,200 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€64,211 | -€57,221 | +€6,990 | +10.9% |
| Amounts payable | 17/49 | €157,232 | €142,813 | -€14,420 | -9.2% |
| Amounts payable after more than one year | 17 | €65,286 | €51,110 | -€14,175 | -21.7% |
| Financial debts | 170/4 | €65,286 | €51,110 | -€14,175 | -21.7% |
| Amounts payable within one year | 42/48 | €91,947 | €91,703 | -€244 | -0.3% |
| Current portion of amounts payable after more than one year | 42 | €13,990 | €14,175 | +€185 | +1.3% |
| Financial debts | 43 | €75,000 | €75,000 | = | 0.0% |
| Credit institutions | 430/8 | €75,000 | €75,000 | = | 0.0% |
| Trade debts | 44 | €280 | €145 | -€135 | -48.3% |
| Suppliers | 440/4 | €280 | €145 | -€135 | -48.3% |
| Taxes, remuneration and social security | 45 | €295 | - | -€295 | |
| Taxes | 450/3 | €295 | - | -€295 | |
| Other amounts payable | 47/48 | €2,382 | €2,382 | = | 0.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €8,648 | €8,648 | = | 0.0% |
| Other operating charges | 640/8 | €2,137 | €2,147 | +€10 | +0.5% |
| Gross operating margin | 9900 | €21,054 | €21,846 | +€792 | +3.8% |
| Operating profit (loss) | 9901 | €10,269 | €11,051 | +€782 | +7.6% |
| Financial charges | 65/66B | €5,362 | €4,061 | -€1,301 | -24.3% |
| Recurring financial charges | 65 | €5,362 | €4,061 | -€1,301 | -24.3% |
| Profit (loss) for the period before taxes | 9903 | €4,907 | €6,990 | +€2,083 | +42.4% |
| Profit (loss) for the period | 9904 | €4,907 | €6,990 | +€2,083 | +42.4% |
| Profit (loss) for the period to be appropriated | 9905 | €4,907 | €6,990 | +€2,083 | +42.4% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 9 October 2026 via checked.be.